StreetAlpha.app
Home › Stocks › TSHA

Taysha Gene Therapies, Inc. (TSHA)

Healthcare
$3.72
▼ −1.33%
LAST CLOSE · NOV 20

Taysha Gene Therapies develops gene therapies for severe brain disorders, with its lead candidate aimed at Rett syndrome. It last closed at $3.72 on Nov 20, down 1.33% on the day. The next earnings report for TSHA is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, TSHA reported EPS of -$0.10 on revenue of $0. Over its last 8 reports the stock moved an average of 3.9% the session after earnings. Over the last 12 months TSHA insiders bought $0 of stock on the open market and sold $6.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is TSHA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TSHA.

Key Stats

Last 12 months
Results
Revenue
$5.5M
−13.1% vs a year ago
Net income
−$156.0M
−2844.6% margin
EPS (diluted)
−$0.42
Free cash flow
−$141.7M
−2582.6% margin
Valuation
Market cap
$1.2B
326.0M shares
P/E
–
No P/E while losing money
Price to sales
221.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$422.8M
At Sep 30
Debt
$47.3M
At Sep 30
Shareholder equity
$357.0M
Shares outstanding
326.0M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $2.5M$2.5MFY2022FY2023: $15.5M$15.5MFY2023FY2024: $8.3M$8.3MFY2024FY2025: $9.8M$9.8MFY2025

From TSHA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · Time not announced
Reported EPS
-$0.10
Quarter ended Sep 2026
Year ago EPS
-$0.09
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.07Dec '24Mar 2025: -$0.08Mar '25Jun 2025: -$0.09Jun '25Sep 2025: -$0.09Sep '25Dec 2025: -$0.08Dec '25Mar 2026: -$0.12Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.10Sep '26Latest -$0.10
Revenue by quarter
Dec 2024: $2.0MDec '24Mar 2025: $2.3MMar '25Jun 2025: $2.0MJun '25Sep 2025: $0Sep '25Dec 2025: $5.5MDec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How TSHA moved after its last 8 reports
Average move the session after a report ±3.9%
Nov 12, 2026Time not announced−1.6%
Aug 11, 2026After the close−4.1%
May 6, 2026Time not announced+0.6%
Mar 19, 2026Time not announced+2.5%
Nov 4, 2025Time not announced−4.3%
Aug 12, 2025Time not announced+5.4%
May 15, 2025Time not announced+8.0%
Feb 26, 2025Time not announced−4.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TSHAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TSHA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TSHA

Technical Analysis

TSHA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 11% below its 20 day and 17% below its 50 day average. It is 42% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $3.71, and the nearest resistance the Pivot R1 at $3.81.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.3%/day
Key levels
$7.3052 week high+96.2%
$5.28200 day average+41.9%
$5.15100 day average+38.4%
$4.3550 day average+16.9%
$4.26Swing high (Oct 21)+14.5%
$4.1220 day average+10.8%
$3.81Pivot R1+2.4%
$3.72Last close
$3.71Pivot−0.3%
$3.62Pivot S1−2.7%
$3.4652 week low−7.0%
$3.46Swing low (Oct 14)−7.0%
Indicators
RSI (14)34.73Weak, oversold below 30Neutral
MACD-0.13Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)14.7No clear trend
Williams %R-87.1Oversold below −80, overbought above −20Oversold
CCI (20)-239.8Oversold below −100, overbought above 100Oversold
Rate of change−14.1%Change over 10 sessionsBearish
ATR (14)$0.27Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TSHA

What happened before

See how TSHA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TSHA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TSHA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TSHAHow many large options trades hit TSHA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TSHA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲117 buying vs 80 selling
  • ▲Held by funds +5.2 pts
  • ▼Funds holding -4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding205209−1.9%
In funds' top 1035−40.0%
Held by funds97.1%91.9%+5.3 pts
New / increased25 / 9241 / 99−16.4%
Reduced / sold out52 / 2841 / 23+25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TSHA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TSHA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$6.7M8 sales · 3 insiders
46% of the selling was under pre-arranged trading plans.
2025-12 sold $1.7M2026-01 sold $2.8M2026-02 sold $7K2026-04 sold $892K2026-07 sold $1.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 10Sukumar NagendranPresident and Head of R&DSale plan200,000$6.24$1.2M
Apr 10Sukumar NagendranPresident and Head of R&DSale plan200,000$4.46$892K
Feb 4Kamran AlamCFOSale1,655$4.52$7K
Jan 26Sean P. NolanCEOSale178,101$4.72$840K
Jan 26Sukumar NagendranPresident and Head of R&DSale116,050$4.72$547K
Jan 26Kamran AlamCFOSale102,817$4.72$485K
Every insider buy and sale for TSHA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TSHA insider trades →

From SEC Form 4 filings by TSHA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TSHA is in one of them and how their past TSHA trades turned out.

TSHA in the AI portfolios
Loading…

TSHA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TSHA in an article yet. Here's the latest on the wider market.

TSHA in the news

About Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company based in Dallas, Texas, that develops gene therapies for severe diseases of the central nervous system. Its lead candidate, TSHA-102, is being tested for Rett syndrome, a genetic disorder that mainly affects girls and causes loss of speech, hand use and motor skills. The treatment is still in clinical trials, and its intended users are patients with Rett syndrome and their caregivers.

Headquarters
Dallas, TX